PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

BACKGROUND: Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Lars Henning, Kümmel, Andreas, Görlich, Dennis, Mohr, Michael, Bröckling, Sebastian, Mikesch, Jan Henrik, Grünewald, Inga, Marra, Alessandro, Schultheis, Anne M., Wardelmann, Eva, Müller-Tidow, Carsten, Spieker, Tilmann, Schliemann, Christoph, Berdel, Wolfgang E., Wiewrodt, Rainer, Hartmann, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552388/
https://www.ncbi.nlm.nih.gov/pubmed/26313362
http://dx.doi.org/10.1371/journal.pone.0136023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552388/
https://www.ncbi.nlm.nih.gov/pubmed/26313362
http://dx.doi.org/10.1371/journal.pone.0136023

Ejemplares similares